INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essenlial thrombocythemia myelofibrosis (Post-PV/ET MF)

被引：13
|
作者：
Verstovsek, Srdan [1 ]
Kantarjian, Hagop [1 ]
Pardanani, Animesh
Thomas, Deborah [1 ]
Cortes, Jorge [1 ]
Mesa, Ruben [2 ]
Redman, John [3 ]
Staschen, Carl-Michael [3 ]
Fridman, Jordan [3 ]
Vaddi, Kris [3 ]
Tefferi, Ayalew [2 ]
机构：
[1] MD Anderson Canc Ctr, Leukemia Dept, Houston, TX USA
[2] Mayo Clin, Dept Hematol, Rochester, MN USA
[3] Incyte Corp, Wilmington, DE USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.558.558
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
558
引用
收藏
页码：171A / 171A
页数：1
相关论文
共 50 条
  • [1] A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H. M.
    Pardanani, A.
    Thomas, D. A.
    Cortes, J. E.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Tefferi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] THE SELECTIVE JANUS KINASE (JAK) INHIBITOR, INCB018424, SHOWS EFFICACY IN A PHASE I/II TRIAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H.
    Pardanani, A.
    Thomas, D.
    Cortes, J.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Fridman, J.
    Tefferi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 179 - 179
  • [3] The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ET-MF)
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Thomas, Deborah
    Cortes, Jorge
    Mesa, Ruben A.
    Hogan, William J.
    Redman, John R.
    Erickson-Viitanen, Sue
    Levy, Richard
    Vaddi, Kris
    Bradley, Edward
    Fridman, Jordan
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 622 - 622
  • [4] A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Sandy, Lonette
    Lu, Min
    Yoon, James
    Petersen, Bruce
    Zhang, David
    Ye, Fei
    Newsom, Carrie
    Najfeld, Vesna
    Hochman, Tsivia
    Goldberg, Judith D.
    Hoffman, Ronald
    LEUKEMIA RESEARCH, 2017, 53 : 13 - 19
  • [5] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [6] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
  • [7] A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
    Mascarenhas, John
    Wang, Xiaoli
    Rodriguez, Amelyn
    Xu, Mingjiang
    Gorman, Elaine
    Zhang, Wenyong
    Goldberg, Judith D.
    Najfeld, Vesna
    Hoffman, Ronald
    BLOOD, 2009, 114 (22) : 130 - 131
  • [8] A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2015, 126 (23)
  • [9] Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
    Chen, Xuejun
    Williams, William V.
    Sandor, Victor
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (07): : 721 - 730
  • [10] RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF)
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Gattoni, Elisabetta
    Antonioli, Elisabetta
    Bogani, Costanza
    Tozzi, Lorenzo
    Pieri, Lisa
    Bosi, Alberto
    Rambaldi, Alessandro
    Barbui, Tiziano
    Barosi, Giovanni
    BLOOD, 2009, 114 (22) : 130 - 130
12345